CD19 and lymphoma: Then, gene expression data from resting CD19+ human tonsillar B cells and human SMZL samples were used to define a human SMZL transcriptional signature (B>0; FDR<0.03; Supplementary Data 2), which could then be compared to the mouse lymphomas.